Author

M. Roes

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

F. A. Dick· 2 shared A. Chaikovsky· 1 shared A. Marshall· 1 shared C. Howlett· 1 shared D. T. Passos· 1 shared J. Sage· 1 shared M. DeWeerd· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

7 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

F. A. Dick

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A genome wide CRISPR screen reveals that HOXA9 promotes enzalutamide resistance in prostate cancer

F. A. Dick, M. Roes

A CRISPR screen identifies HOXA9 as a driver of enzalutamide resistance in prostate cancer, with its inhibition showing synergy with enzalutamide.

bioRxiv · Dec 15, 2023Cancer Biology

RB1 deletion in RB-pathway disrupted cells results in DNA damage and cancer progression.

A. Marshall, M. Roes, D. T. Passos, M. DeWeerd, A. Chaikovsky, J. Sage, C. Howlett, F. A. Dick

This study shows that RB1 mutations in already compromised RB-pathway cells increase DNA damage and cancer progression through genomic instability and impaired repair mechanisms.

bioRxiv · Mar 23, 2019Cancer Biology